

Claim Amendments

A listing of the claims, including Claim 117 as amended and Claim 120 as canceled herein is set forth below.

1-116. (Canceled)

117. (Currently Amended) A method of

(a) determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells, or

(b) following the progression of treatment of B-CLL in a patient having a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells,

the method comprising determining whether ~~the~~ a B cell receptors on ~~the~~ a B-CLL cells ~~from the patient~~ is encoded by antibody genes comprising a light chain antibody gene and a heavy chain antibody gene, wherein the light chain antibody gene and the heavy chain antibody gene are selected from the group consisting of V<sub>H</sub>4-39/D6-13/J<sub>H</sub>5/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set I), V<sub>H</sub>4-34/D5-5/J<sub>H</sub>6/V<sub>L</sub>κA17/J<sub>L</sub>κ1/κ2 (Set II), V<sub>H</sub>3-21/J<sub>H</sub>6/V<sub>L</sub>λ3h/J<sub>L</sub>λ3 (Set III), V<sub>H</sub>1-69/D3-16/J<sub>H</sub>3/V<sub>L</sub>κA27/J<sub>L</sub>κ1/κ4 (Set IV), V<sub>H</sub>1-69/D3-10/J<sub>H</sub>6/V<sub>L</sub>λ1c/J<sub>L</sub>λ1 (Set V), V<sub>H</sub>1-02/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set VIa), V<sub>H</sub>1-03/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set VIb), V<sub>H</sub>1-18/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1 (Set VIc), V<sub>H</sub>1-46/D6-19/J<sub>H</sub>4 (Set VId), V<sub>H</sub>5-51/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ2 (Set VIe), V<sub>H</sub>1-69/D3-3/J<sub>H</sub>4/V<sub>L</sub>κA19/J<sub>L</sub>κ4 (Set VII), and V<sub>H</sub>1-69/D2-2/J<sub>H</sub>6/V<sub>L</sub>κL6/2/J<sub>L</sub>κ3 (Set VIII),

wherein if the B cell receptors on the B-CLL cells ~~have~~ has an idiotype encoded by the antibody genes, the patient has a form of B-CLL susceptible to ~~the~~ treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells or the treatment of the patient has not eliminated the idiotype-specific B cell receptor-bearing B-CLL cells.

118. (Previously Presented) The method of claim 117, for determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells.

119. (Previously Presented) The method of claim 117, for following the progression of treatment of B-CLL in a patient having a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells.

120. (Canceled)

121. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is  $V_H4-34/D5-5/J_H6/V_L\kappa A17/J_L\kappa 1/\kappa 2$  (Set II).

122. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is  $V_H3-21/J_H6/V_L\lambda 3h/J_L\lambda 3$  (Set III).

123. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is  $V_H1-69/D3-16/J_H3/V_L\kappa A27/J_L\kappa 1/\kappa 4$  (Set IV).

124. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is  $V_H1-69/D3-10/J_H6/V_L\lambda 1c/J_L\lambda 1$  (Set V).

125. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is  $V_H1-02/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa 1/\kappa 2$  (Set VIa).

126. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is  $V_H1-03/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa 1/\kappa 2$  (Set VIb).

Applicants : Bradley T. Messmer, Nicholas Chiorazzi and Emilia Albesiano  
Application No. : 10/575,671  
Filing Date : July 25, 2008  
Page 4 of 8

127. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-18/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1 (Set VIc).

128. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-46/D6-19/J<sub>H</sub>4 (Set VIId).

129. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>5-51/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ2 (Set VIe).

130. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-69/D3-3/J<sub>H</sub>4/V<sub>L</sub>κA19/J<sub>L</sub>κ4 (Set VII).

131. (Previously Presented) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-69/D2-2/J<sub>H</sub>6/V<sub>L</sub>κL6/2/J<sub>L</sub>κ3 (Set VIII).

132. (Previously Presented) The method of claim 117, wherein the patient is pre-leukemic.

133. (Previously Presented) The method of claim 117, wherein the patient is in an early leukemic state.

134. (Previously Presented) The method of claim 117, wherein the patient is in a frank leukemic state.

135. (Previously Presented) The method of claim 117, wherein the B-CLL cells from blood of the patient are evaluated.